

A – DEMOGRAPHICS

Date of Initial Screening: ____ / ____ / ____

Patient Age: _____

Date of Fracture: ____ / ____ / ____

Sex/Gender:

Male Female N/A

Race/Ethnicity:

- Black or African American
- American Indian or Alaska Native
- Asian (including Indian subcontinent)
- White
- Hispanic or Latinx
- Native Hawaiian or Pacific Islander
- Other (i.e., mixed race)

BMI: _____

B – CURRENT FRACTURE

Site of Current Fracture (check all that apply):

Upper Limb:

- Shoulder
 - Clavicle Proximal Humerus Scapula
- Arm (Humeral Shaft)
- Elbow
 - Distal Humerus Proximal Radius and/or Ulna
- Forearm (Radius/Ulna Shaft)
- Wrist
 - Distal Radius Carpal Bones

Axial:

- Spine
 - Cervical Lumbar Thoracic Sacrum
- Ribs
- Pelvic Ring

Lower Limb:

- Hip
 - Acetabulum Proximal Femur
- Thigh (Femoral Shaft)
- Knee
 - Distal Femur Proximal Tibia Patella
- Leg (Tibia/Fibular Shafts)
- Ankle/Foot
 - Distal Tibia or Ankle Tarsal Bone

None/Bone Health Optimization

C – FRACTURE HISTORY

History of fracture at the age of 50 or older?

Yes No

If yes, check all that apply:

Upper Limb:

- Shoulder Age at time of fracture: _____
- Arm Age at time of fracture: _____
- Elbow Age at time of fracture: _____
- Forearm Age at time of fracture: _____
- Wrist Age at time of fracture: _____

Axial:

- Spine Age at time of fracture: _____
- Ribs Age at time of fracture: _____
- Pelvic Ring Age at time of fracture: _____

Lower Limb:

- Hip Age at time of fracture: _____
- Thigh (Femoral Shaft) Age at time of fracture: _____
- Knee Age at time of fracture: _____
- Leg (Tibia/Fibular Shafts) Age at time of fracture: _____
- Ankle/Foot Age at time of fracture: _____

D – RISK FACTORS

Risk factors:

- Vitamin D insufficiency (history and/or confirmed by lab work)
- Alcohol consumption (3 or more drinks per day)
- Current smoking (within last 12 months)
- History of falls (2 or more in preceding year)
- Parental history of hip fracture after the age of 50
- Parental history of osteoporosis
- Premature menopause

If the patient has been on any of the medications listed below at the time of fracture or in the past, please indicate that by checking the box beside the appropriate medication.

- Anticonvulsants
- Aromatase inhibitors
- Cancer therapy drugs
- Oral glucocorticoids > or = 5mg/d prednisone for > or = 3 mo.
- Gonadotrophin releasing hormone agonists
- Lithium
- Proton pump inhibitors (PPIs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Thiazolidinediones (TZDs)

Medical diseases/disorders:

- Rheumatoid arthritis

E – MEDICATION USE (HISTORY/DURATION)

If the patient has been on any of the medications listed below at the time of fracture or in the past, please indicate that by checking the box beside the appropriate medication. of the medications checked, please indicate how many years the patient has been on each:

Nutritional Supplements:

- Calcium Vitamin D

Bisphosphonates:

- Alendronate (Fosamax®)
 - < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown
- Ibandronate intravenous injection (Boniva®)
 - < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown
- Ibandronate oral (Boniva®)
 - < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown
- Pamidronate (Aredia®)
 - < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown
- Risedronate (Actone®)
 - < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

- Zoledronate (Actone®)
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown
- If other/unlisted bisphosphonate, please specify: _____
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

Calcitonin:

- Calcitonin (Fortical®)
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown
- Calcitonin injection or Nasal Spray (Miacalcin®)
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

Estrogen/Hormone Therapy (ET/HT) (commonly known as HRT):

- Estrogen/Hormone Therapy
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

Estrogen Agonist/Antagonist (formerly known as SERMs):

- Raloxifene (Evista®)
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown
- If other Estrogen Agonist/Antagonist Therapy, please specify: _____
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

Parathyroid Hormone:

- Teriparatide (Forteo®) < 1 yr 1-3 yrs Unknown
- Abaloparatide (Tymlos®) < 1 yr 1-3 yrs Unknown
- If other Parathyroid Hormone Therapy, please specify: _____
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

RANKL inhibitor/Denosumab:

- Denosumab (Prolia®)
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

Sclerostin inhibitor:

- Romosozumab-aqqg (Evenity®)
 < 1 yr 1-3 yrs 3-5 yrs > 5 yrs Unknown

F – TREATMENT/COUNSELING

Counseling:

Calcium 1200 mg/day (in divided doses)

- Yes No N/A

Vitamin D at least 800-1000 iu/day

- Yes No N/A

Regular weight bearing and muscle strengthening exercise

- Yes No N/A

Fall prevention

- Yes No N/A

Smoking Cessation

- Yes No N/A

Alcohol consumption (no more than an average of 2 drinks per day)

- Yes No N/A

G – PHARMACOLOGIC TREATMENT

Was pharmacologic treatment discussed with or recommended to patient? Yes No N/A

Was new and/or continuation of previous pharmacologic therapy initiated? Yes No

If no, please select one of the following:

- Referred to Primary Care Physician
 Bone health assessment ongoing
 Patient refused treatment
 Patient entering hospice care
 Cost of medicine
 Not indicated
 Other, please specify: _____

If yes, please check all that apply:

- Alendronate (Fosamax®)
 Ibandronate intravenous injection (Boniva®)
 Ibandronate oral (Boniva®)
 Pamidronate (Aredia®)
 Risedronate (Actonel®)
 Zoledronate (Reclast®)
 Other/unlisted bisphosphonate, please specify: _____

Estrogen/Hormone Therapy (ET/HT) (commonly known as HRT):

- Estrogen/Hormone Therapy

Estrogen Agonist/Antagonist (formerly known as SERMs):

- Raloxifene (Evista®)
 If other Estrogen Agonist/Antagonist Therapy, please specify: _____

Parathyroid Hormone:

- Teriparatide (Forteo®)
 Abaloparatide (Tymlos®)
 If other Parathyroid Hormone Therapy, please specify: _____

Denosumab: Denosumab (Prolia®)

Sclerostin inhibitor: Romosozumab-aqqg (Evenity®)

H – BONE MINERAL DENSITY TESTING

Was Bone mineral Density (BMD) testing recommended to patient? Yes No No-not indicated

Bone mineral Density (BMD) testing:

- Performed
 Planned/Scheduled
 Not performed or planned
 N/A (BMD has been tested within the past two years)

Date of BMD test: ____ / ____ / ____

Lumbar Spine T-Score: _____

Lumbar Spine BMD g/cm²: _____ g/cm²

Femoral Neck T-Score: _____

Femoral Neck BMD g/cm²: _____ g/cm²

Distal Forearm T Score (If spine and/or hip technically not available): _____

Distal Forearm BMD g/cm² (If spine and/or hip technically not available): _____ g/cm²

Type of Densitometer:

- Hologic Lunar (GE) Norland Other

If Other Densitometer, specify: _____

- Type of Densitometer Unknown

I – WRITTEN COMMUNICATION & DISCHARGE

Was the patient provide with a letter recommendation specific steps to be taken in order to reduce the risk of a future fracture? Yes No

Was a letter generated for the primary care physician emphasizing the need to take specific steps with the patient in order to reduce the risk of a future fracture? Yes No

Discharge status:

- Routine discharge to home or self care (routine discharge)
 Discharged/transferred to home under health service organization
 Discharged/transferred to skilled nursing facility (SNF)/rehab facility
 Discharged/transferred to long term/extended care facility (nursing home)
 Discharged/transferred to hospice care
 Expired in a medical facility